Abstracts Archive - Page 332 of 2607 - ACR Meeting Abstracts

Abstract Number: 0468 • ACR Convergence 2024
Plasma Calprotectin Assessed in Multiple Biological Treatment Strategies for Early Rheumatoid Arthritis over 48 Weeks
David Stevens¹, Lene Sundbakk², Amirhossein Kazemi², Marte Heiberg³, Tuulikki Sokka-Isler⁴, Bjorn Gudbjornsson⁵, Kristina Lend⁶, Anna Rudin⁷, Michael Nurmohamed⁸, Jon Lampa⁹, Merete Hetland¹⁰, Mikkel Ostergaard¹¹, Ronald Van Vollenhoven¹², Tillmann Uhlig², Espen Haavardsholm² and Hilde Hammer³, ¹St. Olavs hospital, Trondheim, Norway, ²Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Oslo, Norway, ⁴University of Eastern Finland, Faculty of Health Sciences, Jyvaskyla, Finland, ⁵Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ⁶Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ⁷Institute of Medicine, University of Gothenburg, Gothenburg, Sweden, ⁸Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁹Karolinska University Hospital, Hässelby, Sweden, ¹⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ¹¹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ¹²Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Plasma calprotectin is a sensitive biomarker of inflammation in patients with rheumatoid arthritis (RA) and reflects activation of granulocytes and macrophages. Calprotectin has not…
Abstract Number: 0459 • ACR Convergence 2024
Tocilizumab Demonstrates Superior Inhibition of MMP-Mediated Basement Membrane Collagen Degradation Compared to Methotrexate or Placebo
Dovile Sinkeviciute¹, Sofie Falkenloeve Madsen², Nicolas Willumsen³, Patryk Drobinski³, Morten Karsdal³ and Anne-Christine Bay-Jensen³, ¹Nordic Bioscience, Herlev, Hovedstaden, Denmark, ²University of Copenhagen, Copenhagen N, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) pathogenesis involves a range of immune cells, for instance T-cells, neutrophils and macrophages. They produce proinflammatory factors, such as proteolytic enzymes,…
Abstract Number: 0458 • ACR Convergence 2024
Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Sara Achenbach³ and Elena Myasoedova², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
Abstract Number: 0445 • ACR Convergence 2024
Evaluating Clinical Reasoning in Randomized Surveys of Lupus Nephritis and Preeclampsia Pregnancy Case Workups: A Clinical Conundrum
Liya Stolyar¹, Sadaf Sediqi², Richard Lafayette³, Maurice Druzin⁴, Saadiya Hawa⁵, Amanda Moyer⁶, Yashaar Chaichian² and Julia Simard², ¹Palo Alto VA Medical Center/Stanford, Stanford, CA, ²Stanford School of Medicine, Stanford, CA, ³Stanford, Stanford, CA, ⁴Stanford University School of Medicine, Stanford, CA, ⁵Weiss Memorial Hospital, Chicago, IL, ⁶Stanford University, San Bruno, CA
Background/Purpose: Systemic lupus erythematosus (SLE) pregnancy is associated with a heightened risk of adverse pregnancy outcomes, including preeclampsia. Distinguishing preeclampsia from lupus nephritis (LN) presents…
Abstract Number: 0467 • ACR Convergence 2024
Lung Involvement in Early Rheumatoid Arthritis, Analysis of ERA UCLouvain Brussels FINDRA Cohort
FROIDURE Antoine¹, DOYEN Marie², PERROT Marie¹, GHAYE Benoit³, SAPART Emilie⁴, BEARZATTO Bertrand⁵, DURANT Jean-François⁵, AMBROISE Jérôme⁵, GALA Jean-Luc⁵, ZAN Deniz³, AVRAMOVSKA Aleksandra⁴, SOKOLOVA Tatiana⁴, KOENIG Sandra² and DUREZ Patrick⁴, ¹Pulmonology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Radiology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ⁵Institute de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium
Background/Purpose: The prevalence of lung involvement in rheumatoid arthritis (RA) remains elusive. We set up a prospective study to detect ILD, bronchiolitis and nodules in…
Abstract Number: 0480 • ACR Convergence 2024
Can’t Sleep, Won’t Sleep: A Systematic Review and Meta-Analysis of Insomnia Prevalence in 70,105 Rheumatoid Arthritis Patients
Mohamed Abdelsalam¹, Mamdouh Ahmed Khairy², Mohamed Reda Awad³, Aly Alnabawy², Maryam Taha⁴ and Mohamed Al-Adl Ali Ali², ¹Rheumatology, Rehabilitation and Physical medicine department - faculty of medicine -Misr University for science and technology, 6th of October, Al Jizah, Egypt, ²Faculty of medicine - Al-Azhar university Cairo branch, Cairo, Egypt, ³Al Azhar University, Cairo, Egypt, Giza, Egypt, ⁴Faculty of medicine - Ain Shams university, Madinat Nasr, Al Qahirah, Egypt
Background/Purpose: Insomnia is a significant challenge for rheumatoid arthritis (RA) patients. Chronic pain conditions often exacerbate sleep disturbances, creating a vicious cycle where pain and…
Abstract Number: 0301 • ACR Convergence 2024
Path to Diagnosis in Familial Mediterranean Fever (FMF)
Sejla Karup¹, Dila Polat², Erengul Dincsoy², Feyza Nur Azman², Mahir Emir Cokrak², Ertan Berkiten² and Serdal Ugurlu³, ¹Cerrahpasa Faculty of Medicine, Istanbul, Turkey, ²Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Familial Mediterranean Fever (FMF) is a genetic disorder characterized by recurrent febrile episodes and inflammation, most commonly presenting with peritonitis, pleuritis, and arthritis. The…
Abstract Number: 0198 • ACR Convergence 2024
COVID-19 Vaccination and Hospitalization Rates Differ Between People with Diagnosed Immune Mediated Inflammatory Disease and the General Population: A Population-based Study
Carol Hitchon¹, Carole Taylor¹, Charles N Bernstein¹, Christine Peschken¹, J. Antonio Avina-Zubieta², Sasha Bernatsky³, Gil Kaplan⁴, Diane Lacaille², Jessica Widdifeild⁵ and RuthAnn Marrie¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: People with immune mediated inflammatory diseases (IMIDs) are at greater risk of severe Coronavirus disease (COVID-19). Vaccination reduces COVID-19 severity however, vaccine uptake may…
Abstract Number: 0425 • ACR Convergence 2024
Use of bDMARDs During Pregnancy After Preconceptional Counseling in Spanish Patients with Rheumatic Diseases
Antia Garcia Fernandez¹, Fernando Rengifo-Garcia¹, Raquel Senosiain-Echarte¹, Miguel Álvaro Navidad¹, Miguel Angel Gonzalez-Gay² and Juan Antonio Martínez - López¹, ¹Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ²University of Cantabria, Fundación Jimenez Díaz, Madrid, Madrid, Spain
Background/Purpose: Current recommendations advocate maintaining pregnancy-compatible bDMARDs during pregnancy (mainly TNF inhibitors) and monitoring disease activity before conception to improve disease and pregnancy outcomes. Recently,…
Abstract Number: 0415 • ACR Convergence 2024
Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis
narendra bagri, Sushain Kalsotra, vandana jain, Manisha Jana, Maroof Ahmed Khan, Yashdeep Gupta and Sumit Kumar Das, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disease in children less than 16 years of age. Various factors have been suggested…
Abstract Number: 0479 • ACR Convergence 2024
Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis
Shant Ayanian, Collin Osborne, Marc Blasi, Daniel Darveaux, Eric Klee and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…
Abstract Number: 0435 • ACR Convergence 2024
Use of Contraception in Women of Childbearing Age with Immune-Mediated Rheumatic Diseases: Experience from an Italian Centre
Clizia Gagliardi¹, Maria Chiara Gerardi², Eleonora Giacobbe³, Sara Benedetti², Giuseppina Di Raimondo², Assunta Ascione³, Monica Barichello², Nicola Ughi⁴, Antonella Adinolfi², Laura Belloli², Cinzia Casu², Maria Di Cicco², Davide antonio Filippini², Matteo Longhi², Bianca Lucia Palermo², Martina Schettino², Giulia Segatto², Elisa Verduci² and Oscar Massimiliano Epis², ¹Niguarda Hospital, Milan, Bergamo, Italy, ²Niguarda Hospital, Milan, Milan, Italy, ³Niguarda Hospital, Milan, Milan, ⁴Niguarda Hospital, Milan, Mila, Italy
Background/Purpose: Contraception is a relevant issue for women of childbearing age with immune-mediated rheumatic diseases, as an unplanned pregnancy during active disease or treatment with…
Abstract Number: 0448 • ACR Convergence 2024
A Pregnant Lupus Patient’s Journey: Single-Center Outcomes and Opportunities
Divya Singh¹, Maya Faison², Molly Leavitt³, Megan Clowse⁴ and Cuoghi Edens⁵, ¹University of Chicago, Chicago, IL, ²University of Chicago, Chapel Hill, NC, ³MacNeal Hospital/Loyola Medicine, Chicago, IL, ⁴Duke University, Chapel Hill, NC, ⁵Section of Pediatric Rheumatology, Section of Rheumatology, University of Chicago, Chicago, IL
Background/Purpose: Nearly half of systemic lupus erythematosus (SLE) patients will experience pregnancy complications. These complications include increased rates of prematurity, miscarriage, pre-eclampsia, and mortality. Maternal…
Abstract Number: 0306 • ACR Convergence 2024
Cardiovascular Risk Estimated with the New PREVENT Calculator and Disease Activity in Patients with Rheumatoid and Psoriatic Arthritis
Aleydis Gonzalez Melendez¹, Rebeca L. Polina-Lugo¹, Maria F. Elizondo-Benitez², Andrea Guajardo Aldaco¹, Osvaldo Uresti³, Ricardo I. de la Rosa-Vazquez³, Iris Jazmín Colunga Pedraza¹, Dionicio Galarza-Delgado⁴, jose Ramon Azpiri-Lopez⁵, Rosa Icela Arvizu-Rivera¹ and Jesus Cardenas-de la Garza⁶, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ³Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo León, Mexico, ⁴UANL Hospital Universitario, Monterrey, Nuevo León, Mexico, ⁵Division of Cardiology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁶Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico
Background/Purpose: The American Heart Association's PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) is a new calculator developed in 2024, which estimates the 10- and 30-year…
Abstract Number: 0324 • ACR Convergence 2024
Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
Daniel Nunez¹, Jenell Volkov¹, Jason Stadanlick¹, Zachary Vorndran¹, Alexandra Ellis¹, Mallorie Werner¹, Justin Cicarelli¹, Jazmean Williams¹, Fatemeh Nezhad¹, Thomas Furmanak², Quynh Lam¹, Rebecca Estremera¹, Yvonne White¹, Jonathan Hogan¹, Claire Miller¹, Tahseen Mozaffar³, Saira Sheikh⁴, David Chang¹ and Samik Basu¹, ¹Cabaletta Bio, Philadelphia, PA, ²Cabaletta Bio - Philadelphia, PA, Philadelphia, PA, ³The University of California, Irvine, Orange, CA, ⁴University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: CD19 targeting chimeric antigen receptor (CAR) T cells have demonstrated durable drug-free responses and remission in patients with idiopathic inflammatory myopathies (IIM) and systemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].